...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen.
【24h】

Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen.

机译:在接受环孢素+雷帕霉素治疗的肾移植受者中,外周淋巴细胞的刺激反应可能区分环孢素的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Clinically, cyclosporine (CSA, Neoral) is titrated to concentrations, and not to pharmacological effect. METHODS: Intracellular interleukin- (IL) 2 was measured in phorbol myristic acid-ionomycin-stimulated peripheral lymphocytes by flow cytometry, after isolation from 14 renal transplant recipients receiving CSA+prednisone, and double-blind rapamycin (rapamycin:placebo=4:1). RESULTS: The proportion (%) of CD4+IL-2+ lymphocytes corresponding to CSA levels (mean+/-SD ng/ml) measured preoperatively (TO=O), and on postoperative day 8, before (356+/-63), and 2 hr after the morning dose (Cmax=1567+/-669), decreased from 39+/-16 to 15+/-8 and 3+/-1.6, respectively. Reciprocally, unresponsive lymphocytes (%CD4+IL-2-) increased with increasing CSA levels and predicted an EC50 of 249 ng/ml (CSA concentration at which CD4+IL-2- cells increased by 50% over baseline) in an Emax pharmacodynamic model. CONCLUSIONS: Clinically, the pharmacological effect of CSA is quantifiable, and lies in the upper end of the predicted range. In our Neoral-treated sample population, Cmax was associated with the least variable "cyclosporine effect." Such information could potentially individualize immunosuppression, and lead to rational dosing strategies.
机译:背景:临床上,将环孢霉素(CSA,Neoral)滴定至浓度而不是药理作用。方法:从14名接受CSA +泼尼松的肾移植受者和双盲雷帕霉素(雷帕霉素:安慰剂= 4:1)分离后,通过流式细胞术在佛波肉豆蔻酸-离子霉素刺激的外周血淋巴细胞中测量细胞内白介素(IL)2。 )。结果:与术前(TO = O)和术后第8天(356 +/- 63)之前测量的CSA水平(平均+/- SD ng / ml)相对应的CD4 + IL-2 +淋巴细胞比例(%)。和早晨剂量(Cmax = 1567 +/- 669)2小时后分别从39 +/- 16降至15 +/- 8和3 +/- 1.6。相反,在Emax药效学中,无反应的淋巴细胞(%CD4 + IL-2-)随着CSA水平的增加而增加,并预测EC50为249 ng / ml(CSA浓度,其中CD4 + IL-2-细胞比基线增加50%)。模型。结论:在临床上,CSA的药理作用是可量化的,处于预测范围的上限。在我们的经Neoral治疗的样本人群中,Cmax与变量“环孢菌素效应”变化最小。这些信息可能会潜在地使免疫抑制个性化,并导致合理的剂量策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号